299916-78-2

Basic information

• Product Name: 5H-Pyrrolo3,2-dpyrimidine, 7-bromo-4-(1,1-dimethylethoxy)-5-(phenylmethoxy)methyl-
• Synonyms: 5H-Pyrrolo3,2-dpyrimidine, 7-bromo-4-(1,1-dimethylethoxy)-5-(phenylmethoxy)methyl-
• CAS NO: 299916-78-2
• Molecular Formula: C₁₈H₂₀BrN₃O₂
• Molecular Weight: 390.2743
• Mol File: 299916-78-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5H-Pyrrolo3,2-dpyrimidine, 7-bromo-4-(1,1-dimethylethoxy)-5-(phenylmethoxy)methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-Pyrrolo3,2-dpyrimidine, 7-bromo-4-(1,1-dimethylethoxy)-5-(phenylmethoxy)methyl-(299916-78-2)
• EPA Substance Registry System: 5H-Pyrrolo3,2-dpyrimidine, 7-bromo-4-(1,1-dimethylethoxy)-5-(phenylmethoxy)methyl-(299916-78-2)

Safety Data

• Hazardous Substances Data: 299916-78-2(Hazardous Substances Data)

Upstream product

• 3587-60-8 Benzyloxymethyl chloride 
• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 

Downstream Products

• 635319-12-9 7-benzyloxymethyl-6-O-tert-butyl-9-deaza-9-formylhypoxanthine 
• 666830-86-0 (3R,4R)-1-[(7-benzyloxymethyl-9-deazahypoxanthin-9-yl)methyl]-3-benzyloxy-4-benzyloxymethylpyrrolidine 
• 635319-15-2 7-(3-benzyloxy-4-benzyloxymethyl-pyrrolidin-1-ylmethyl)-5-benzyloxymethyl-4-tert-butoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 299917-26-3 (1S)-1-(7-N-benzyloxymethyl-6-O-tert-butyl-9-deaza-hypoxanthin-9-yl)-N-tert-butoxycarbonyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
• 402477-19-4 (1S)-1-(7-N-benzyloxymethyl-6-O-tert-butyl-9-deaza-8-fluorohypoxanthin-9-yl)-N-tert-butoxycarbonyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 

Relevant articles and documents

PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.

Process for preparing 2-pyrrolidinyl-1H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism

A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted all, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II) ?with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX), ?to form a compound of formula (XX) The compound of formula (XX) is N- and O-deprotected to obtain the compound of formula (I).

Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase

The aza-C-nucleosides, Immucillin-H and Immucillin-G, are transition state analogue inhibitors of purine nucleoside phosphorylase, a therapeutic target for the control of T-cell proliferation. Immucillin analogues modified at the 2′-, 3′-, or 5′-positions of the azasugar moiety or at the 6-, 7-, or 8-positions of the deazapurine, as well as methylene -bridged analogues, have been synthesized and tested for their inhibition of human purine nucleoside phosphorylase. All analogues were poorer inhibitors, which reflects the superior capture of transition state features in the parent immucillins.